Denali Therapeutics has filed a patent for crystalline forms of a compound called (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide. The patent also covers the process of preparing these forms and their use in pharmaceutical compositions. The patent claim lists six different crystalline forms of the compound. GlobalData’s report on Denali Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Denali Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Denali Therapeutics's grant share as of September 2023 was 16%. Grant share is based on the ratio of number of grants to total number of patents.
Crystalline forms of a specific compound and their preparation
A recent patent application (Publication Number: US20230271978A1) describes various crystalline forms of a compound called (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide. The patent claims six different crystalline forms of the compound, labeled as Form A, Form B, Form C, Form D, Form E, and Form F. Each form has a unique X-ray powder diffraction pattern and differential scanning calorimetry (DSC) curve.
Form A of the compound is characterized by an X-ray powder diffraction pattern with peaks at specific 2-theta degrees, including 6.9, 11.5, 13.0, 13.9, 16.6, 19.4, 23.4, and 24.0±0.2 degrees. It also exhibits a DSC curve with an onset at about 186.7° C. and an endothermic peak at 188.9° C.
Form B of the compound has an X-ray powder diffraction pattern with a peak at about 9.6 and 16.4±0.2 degrees. It also shows an endotherm at about 189.2° C. and an endothermic peak at 191.9° C. in its DSC curve.
Form C of the compound has an X-ray powder diffraction pattern with peaks at specific 2-theta degrees, including 9.8, 10.2, 14.8, 15.2, 18.1, 20.4, and 22.3±0.2 degrees. Its DSC curve exhibits an endotherm at about 124.9° C. and an endothermic peak at 131.3° C.
The patent also discloses a pharmaceutical composition comprising any of the crystalline forms of the compound and a pharmaceutically acceptable excipient. Additionally, the patent claims a method of treating a disease or disorder mediated by RIPK1 in a patient by administering an effective amount of any of the crystalline forms of the compound.
These crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide have unique characteristics and may have potential applications in the field of pharmaceuticals for the treatment of diseases or disorders mediated by RIPK1. The patent application provides detailed information about the specific X-ray powder diffraction patterns and DSC curves for each form, allowing for their identification and potential use in drug development.
To know more about GlobalData’s detailed insights on Denali Therapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
